MOA full Copyright

Membrane Interaction  

The Shuttle interacts strongly with the membrane to initiate the permeabilization process.

Membrane Interaction

Endosomal Leakage

While the Shuttle remains in the membrane, the free therapeutic compound translocates to the cytoplasm.

Endosomal Leakage

Characteristics of the Feldan Shuttle

The Feldan Shuttle provides a unique way to deliver therapeutic compounds inside cells and is allowing the development of next-generation therapies.

  • Peptide-based 
  • Fast degradation 
  • No toxic metabolites
  • Safe for in vivo use
  • Delivery of peptides, proteins and antisense oligonucleotides (ASOs)
  • Circumvents endosomal entrapment 
  • Performs fast delivery on multiple cell types, ex vivo and in vivo

Correcting Diseases by Modulating Intracellular Pathways

The Feldan Shuttle allows untapped and highly specific therapeutics compounds to access intracellular pathways that can be targeted for therapeutic interventions. The versatility of the technology translates into multiple strategies to correct diseases:


Repressing Pathogenic Pathways

Having access to the intracellular space allows the targeting and correction of dysregulated proteins and signalling pathways associated with diseases. 

Supplying Missing Proteins

The Feldan Shuttle allows the development of a new generation of therapies for diseases caused by the absence of intracellular proteins.

Rewriting Impaired Genes

The Feldan Shuttle allows the delivery of gene-editing nucleases in their active protein form. This allows precise and safe correction of impaired genes.



Engineered amphiphilic peptides enable delivery of proteins and CRISPR-associated nucleases to airway epithelia.

Krishnamurthy S, Wohlford-Lenane C, Kandimalla S, Sartre G, Meyerholz DK, Théberge V, Hallée S, Duperré AM, Del'Guidice T, Lepetit-Stoffaes JP, Barbeau X, Guay D, McCray PB Jr.,  Nat Commun. 2019 Oct 28;10(1):4906. doi: 10.1038/s41467-019-12922-y.  PMID: 31659165


Plos One

Membrane permeabilizing amphiphilic peptide delivers recombinant transcription factor and CRISPR-Cas9/Cpf1 ribonucleoproteins in hard-to-modify cells.

Del'Guidice T, Lepetit-Stoffaes JP, Bordeleau LJ, Roberge J, Théberge V, Lauvaux C, Barbeau X, Trottier J, Dave V, Roy DC, Gaillet B, Garnier A, Guay D. PLoS One. 2018 Apr 4;13(4):e0195558. doi: 10.1371/journal.pone.0195558. eCollection 2018. PMID:29617431